NEUREN PHARMACEUTICALS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.25 AUD | +3.22% |
|
-0.16% | -22.91% |
| Apr. 24 | Neuren Pharmaceuticals Posts AU$243 Million Cash, Short-Term Investments | MT |
| Apr. 23 | Neuren Pharmaceuticals' Medication Secures Priority Review from Health Canada | MT |
Presenter SpeechGerry Zhao (Executives)Good afternoon. Welcome to Neuren's 2023 Financial Resu...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing therapies for neurodevelopmental disorders. The Company is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Companyâs product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product NNZ-2591 is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The Company has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of trofinetide.
Sector
Pharmaceuticals
Calendar
2024-05-28
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
18.65
AUD
Average target price
26.74
AUD
Spread / Average Target
+43.36%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -22.91% | 1.55B | |
| +25.81% | 661B | |
| +26.77% | 566B | |
| -6.71% | 352B | |
| +20.38% | 332B | |
| +2.48% | 283B | |
| +13.53% | 231B | |
| +4.80% | 200B | |
| -9.37% | 195B | |
| -5.31% | 145B |
- Stock Market
- Equities
- NEU Stock
- News Neuren Pharmaceuticals Limited
- Transcript : Neuren Pharmaceuticals Limited, Q4 2023 Earnings Call, Feb 29, 2024
